NCT07037862 - A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

March 28, 2029

Study Completion Date

March 28, 2029

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

DRUG

ENTR-601-44

intravenous infusion

DRUG

ENTR-601-44 - matching placebo

intravenous infusion

Trial Locations (14)

3000

RECRUITING

UZ Leuven, Leuven

4000

NOT_YET_RECRUITING

Centre Hospitalier Régional de la Citadelle, Liège

9000

RECRUITING

University Hospital Gent, Ghent

20132

NOT_YET_RECRUITING

IRCCS Ospedale San Raffaele, Milan

20162

NOT_YET_RECRUITING

Fondazione Serena Onlus - Centro Clinico NeMO Milano, Milan

00165

NOT_YET_RECRUITING

Ospedale Pediatrico Bambino Gesu, Rome

00168

NOT_YET_RECRUITING

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome

08035

RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona

08950

NOT_YET_RECRUITING

Hospital Sant Joan de Deu, Barcelona

LS1 3EX

NOT_YET_RECRUITING

Leeds General Infirmary, Leeds

L122AP

NOT_YET_RECRUITING

Alder Hey Children's NHS Foundation Trust, Liverpool

WC1N 3JH

NOT_YET_RECRUITING

Great Ormond Street Hospital for Children, London

NE1 3BZ

NOT_YET_RECRUITING

Freeman Hospital, Newcastle upon Tyne

OX3 9DU

NOT_YET_RECRUITING

Oxford University Hospitals NHS Foundation Trust, Oxford